Plus Therapeutics (PSTV) Liabilities and Shareholders Equity (2010 - 2026)

Plus Therapeutics (PSTV) has 17 years of Liabilities and Shareholders Equity data on file, last reported at $19.9 million in Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $19.9 million, up 65.2% year-over-year; the trailing twelve-month figure through Mar 2026 was $65.3 million (up 76.96% YoY), and the FY2025 annual result was $16.3 million, up 146.12% from the prior year.
• Liabilities and Shareholders Equity grew to $19.9 million in Q1 2026 per PSTV's latest filing, from $16.3 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $24.5 million in Q1 2022 and troughed at $5.6 million in Q1 2024.
• A 5-year average of $15.0 million and a median of $14.2 million in 2023 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2024 and 2025: Liabilities and Shareholders Equity sank 64.06% in 2024, then soared 167.56% in 2025.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $23.9 million in 2022, then tumbled by 52.29% to $11.4 million in 2023, then sank by 41.75% to $6.6 million in 2024, then soared by 146.12% to $16.3 million in 2025, then advanced by 22.0% to $19.9 million in 2026.
• Business Quant data shows PSTV's Liabilities and Shareholders Equity at $19.9 million in Q1 2026, $16.3 million in Q4 2025, and $18.7 million in Q3 2025.